ClinicalTrials.gg
RecruitingNCT07783984Updated Aug 25, 2026

Thoracoscopic Versus Catheter Ablation in Persistent Atrial Fibrillation With Enlarged Left Atrium

An interventional study of Thoracoscopic ablation and Percutaneous catheter ablation in Atrial Fibrillation, Thoracoscopic Ablation and Endocardial Ablation, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Samsung Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 3 months after the study started (first participant enrolled May 2024, registered Aug 2026).
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
194
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Atrial Fibrillation by Samsung Medical Center — 7 open to participants now, 7 under way, none of them phase 3. Atrial Fibrillation · Samsung Medical Center.

Planned enrollment
7th of 11
194 · median 200
Started
2024
with 2 others
No phase
9 of 16
4 open now
Registered
16th of 16
by date

Among the 16 studies in Atrial Fibrillation by Samsung Medical Center, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 with no phase, and was the 16th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 16 studies in Atrial Fibrillation by Samsung Medical Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by Samsung Medical Center, or all of them as a file.
02

Study summary

This is a prospective, single-center, open-label, randomized controlled trial comparing thoracoscopic surgical ablation with percutaneous endocardial catheter ablation as the first rhythm-control procedure in patients with persistent atrial fibrillation and an enlarged left atrium (LA diameter ≥50 mm or LA volume index ≥45 mL/m²).

A total of 194 patients who have never undergone an ablation procedure for atrial fibrillation will be randomly assigned 1:1 to thoracoscopic ablation or percutaneous catheter ablation, stratified by duration of atrial fibrillation. The primary endpoint is recurrence of atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) after a 3-month blanking period. The investigators hypothesize that thoracoscopic ablation will significantly reduce recurrence compared with catheter ablation in this population.

A secondary hypothesis is that 14-day patch monitoring detects recurrent atrial tachyarrhythmia more sensitively than conventional 24-hour Holter monitoring.

Read the detailed description

Pulmonary vein isolation is an established rhythm-control therapy for symptomatic atrial fibrillation refractory to antiarrhythmic drugs. Its efficacy is lower in persistent than in paroxysmal atrial fibrillation, and additional substrate modification of the left atrium is frequently required.

Percutaneous catheter ablation (radiofrequency, cryoballoon or PFA) and thoracoscopic surgical ablation are both used in current practice. Thoracoscopic ablation additionally allows epicardial pulmonary vein isolation, ganglionated plexi ablation, dissection of the ligament of Marshall, and left atrial appendage exclusion, at the cost of a longer hospital stay and a higher incidence of post-procedural pericarditis. Recent trials have shown broadly comparable efficacy and safety between the two approaches, so both are used interchangeably in practice.

In a retrospective analysis of the institutional ablation registry at the study site, overall outcomes of the two strategies were comparable, but among patients with an enlarged left atrium thoracoscopic ablation was associated with significantly lower recurrence of atrial tachyarrhythmia. Because that finding came from a subgroup of a retrospective cohort, it could not support a firm conclusion.

This trial therefore prospectively tests, in patients with persistent atrial fibrillation and an enlarged left atrium undergoing a first rhythm-control procedure, whether thoracoscopic ablation is superior to percutaneous catheter ablation.

Post-procedural management is identical in both arms: a 3-month blanking period, discontinuation of antiarrhythmic drugs at 3 months (up to 6 months) if sinus rhythm is maintained, and anticoagulation for at least 3 months with subsequent decisions based on recurrence, prior stroke, and CHA2DS2-VASc score. Follow-up visits occur at 3, 6, and 12 months and every 6 months thereafter until 1 year after the last patient is enrolled. Rhythm monitoring uses 12-lead ECG, 24-hour Holter (3, 6, 12 months), and 14-day patch monitoring; echocardiography and NT-proBNP are obtained at baseline, 12 months, and annually thereafter.

03

Conditions studied

  • Atrial Fibrillation
  • Thoracoscopic Ablation
  • Endocardial Ablation

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 years or older
  • Persistent atrial fibrillation to antiarrhythmic drug therapy, or in whom antiarrhythmic drug therapy cannot be maintained
  • European Heart Rhythm Association (EHRA) symptom score ≥ 2
  • Considered suitable for rhythm-control therapy by either percutaneous catheter ablation or thoracoscopic ablation, at the investigator's medical discretion
  • Enlarged left atrium, defined as left atrial diameter ≥ 50 mm or left atrial volume index ≥ 45 mL/m²

Exclusion criteria

Exclusion Criteria:

  • Previous percutaneous catheter ablation or thoracoscopic ablation for atrial fibrillation
  • Previous thoracic or cardiac surgery
  • Absolute to anticoagulation therapy
  • less than 1 year due to non-cardiac disease, or anticipated poor adherence to treatment, at the investigator's medical discretion
  • Refusal to participate in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
194 participants (estimated)

Study arms

  • Experimental
    Thoracoscopic ablation

    Thoracoscopic surgical ablation is performed according to the standard technique. Pulmonary vein isolation and left atrial appendage exclusion are mandatory. Additional lesions are at the operator's discretion.

    Procedure: Thoracoscopic ablation

  • Active comparator
    Percutaneous catheter ablation

    Percutaneous endocardial catheter ablation is performed using radiofrequency, cryoballoon, or pulsed field energy. Pulmonary vein isolation is mandatory. Additional lesions are at the operator's discretion.

    Procedure: Percutaneous catheter ablation

Interventions

  • ProcedureThoracoscopic ablation

    Thoracoscopic surgical ablation is performed according to the standard technique. Pulmonary vein isolation and left atrial appendage exclusion are mandatory. Additional lesions are at the operator's discretion.

  • ProcedurePercutaneous catheter ablation

    Percutaneous endocardial catheter ablation is performed using radiofrequency, cryoballoon, or pulsed field energy. Pulmonary vein isolation is mandatory. Additional lesions are at the operator's discretion.

06

What researchers measure

Primary outcomes

  1. Recurrence of atrial tachyarrhythmia

    Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia, defined as an episode documented on 12-lead ECG or sustained for at least 30 seconds on continuous monitoring (14-day patch monitor or 24-hour Holter). Recurrences during the 3-month blanking period are not counted as events.

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

Secondary outcomes

  1. Recurrence of atrial fibrillation

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

  2. Recurrence of atrial flutter

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

  3. Recurrence of atrial tachycardia

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

  4. All-cause death

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

  5. Cardiac death

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

  6. Stroke

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

  7. Hospitalization for heart failure

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

  8. Procedure-related complications

    Time frame: From 3 months after the index procedure until 1 year after enrollment of the last patient

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2028, 48 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 25, 2026
StartActual
May 1, 2024
Primary completionEst.
May 1, 2028
CompletionEst.
May 1, 2029
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07783984
Responsible party
Young Keun On (Professor, Samsung Medical Center) — Principal investigator
First posted
Aug 25, 2026
Start date
May 1, 2024
Primary completion
May 1, 2028 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Aug 25, 2026

Study contacts

Young Keun On, MD, PhD
Contact
yk.on@samsung.com
+82-2-3410-2578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion